Breast Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: BRS044 MIFTS: 54	Breast Adenocarcinoma Categories: Cancer diseases, Rare diseases, Reproductive diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Breast Adenocarcinoma

MalaCards integrated aliases for Breast Adenocarcinoma:

Name: Breast Adenocarcinoma ¹¹ ²⁸ ⁵ ¹⁴ ¹⁶ ⁷¹

Mammary Adenocarcinoma ¹¹ ⁷¹

Adenocarcinoma of Breast ¹¹

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:3458

NCIt ⁴⁹ C5214

SNOMED-CT ⁶⁸ 865954003

EFO ¹⁶ EFO_0000304

UMLS ⁷¹ C0858252 C3669246

Sources

Summaries for Breast Adenocarcinoma

Disease Ontology: ¹¹ A breast carcinoma that originates in the milk ducts and/or lobules (glandular tissue) of the breast.

MalaCards based summary: Breast Adenocarcinoma, also known as mammary adenocarcinoma, is related to mammary paget's disease and oncocytic breast carcinoma. An important gene associated with Breast Adenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Disease and Signal Transduction. The drugs Zoledronic acid and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and lung, and related phenotypes are Decreased viability and Decreased viability in pancreas lineage

Sources

Related Diseases for Breast Adenocarcinoma

Diseases in the Breast Adenocarcinoma family:

Rare Adenocarcinoma of the Breast

Diseases related to Breast Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 482)

#	Related Disease	Score	Top Affiliating Genes
1	mammary paget's disease	32.6	VCP TNFSF11 PIP PGR ESR1 ERBB2
2	oncocytic breast carcinoma	32.5	PIP PGR ESR1 ERBB2
3	glycogen-rich carcinoma	32.5	PIP PGR ERBB2
4	breast mucinous carcinoma	32.5	PIP PGR ERBB2
5	adenocarcinoma	32.5	TP53 PIK3CA KRAS H19 ERBB2 BAX
6	inflammatory breast carcinoma	32.5	PGR ESR1 ERBB2
7	breast apocrine carcinoma	32.3	PIP PGR
8	breast cancer	31.9	TP53 TNFSF11 SLC22A18 RB1CC1 PIP PIK3CA
9	ovary adenocarcinoma	31.0	TP53 PIK3CA PGR KRAS H2AC18 ESR1
10	ductal carcinoma in situ	31.0	TP53 PIP PIK3CA PGR ESR1 ERBB2
11	breast disease	30.9	TP53 PGR H2AC18 ESR1 ERBB2
12	ovarian cancer	30.9	TP53 PIK3CA PGR KRAS H2AC18 H19
13	osteogenic sarcoma	30.8	TP53 TNFSF11 H19 ESR1 BAX AKT1
14	hepatocellular carcinoma	30.8	TP53 TNFSF11 PIK3CA PGR KRAS H2AC18
15	signet ring cell adenocarcinoma	30.8	TP53 PIP KRAS ERBB2
16	colon adenocarcinoma	30.8	TP53 PIK3CA KRAS ESR1 BAX
17	ovarian cystadenocarcinoma	30.7	TP53 PIK3CA KRAS H2AC18 ESR1 ERBB2
18	mixed cell type cancer	30.7	TP53 PIK3CA PGR KRAS H2AC18 ESR1
19	teratoma	30.7	TP53 KRAS H19 ESR1 ERBB2 AKT1
20	gastric adenocarcinoma	30.7	TP53 PIK3CA KRAS H19 ERBB2 AKT1
21	cystadenocarcinoma	30.7	TP53 PGR KRAS AKT1
22	suppression of tumorigenicity 12	30.7	TP53 PIK3CA H2AC18 ERBB2 AKT1
23	mucinous adenocarcinoma	30.7	TP53 PIK3CA KRAS ERBB2
24	comedo carcinoma	30.7	TP53 PGR ESR1 ERBB2
25	small cell cancer of the lung	30.7	TP53 PIK3CA CALCA AKT1
26	glioblastoma	30.6	TP53 PIK3CA KRAS H19 ERBB2 BAX
27	lung cancer susceptibility 3	30.6	TP53 PIP PIK3CA KRAS H2AC18 H19
28	rectal benign neoplasm	30.6	TP53 PIK3CA KRAS
29	estrogen-receptor positive breast cancer	30.6	TP53 PIK3CA PGR H2AC18 ESR1 ERBB2
30	rhabdomyosarcoma	30.6	TP53 SLC22A18 PIK3CA KRAS H19 ESR1
31	gastrointestinal stromal tumor	30.6	TP53 PIK3CA KRAS H2AC18 ESR1 ERBB2
32	meningioma, familial	30.6	TP53 PIK3CA PGR H2AC18 H19 ESR1
33	colorectal adenocarcinoma	30.6	TP53 PIK3CA KRAS H2AC18 ERBB2 AKT1
34	cholangiocarcinoma	30.6	TP53 PIK3CA KRAS H19 ERBB2 AKT1
35	skin squamous cell carcinoma	30.6	TP53 ERBB2 AKT1
36	apocrine adenocarcinoma	30.6	TP53 PIP PIK3CA PGR ESR1 ERBB2
37	squamous cell carcinoma	30.6	TP53 PIK3CA KRAS H19 ERBB2 AKT1
38	head and neck cancer	30.6	TP53 PIK3CA KRAS H2AC18 ERBB2 AKT1
39	premature menopause	30.6	TP53 TNFSF11 PGR ESR1 ERBB2 CALCA
40	adenoma	30.6	TP53 PIK3CA KRAS AKT1
41	female breast cancer	30.6	TP53 PIP PGR ESR1 ERBB2
42	breast malignant phyllodes tumor	30.6	TP53 PGR ESR1 ERBB2
43	leukemia, acute myeloid	30.6	TP53 PIK3CA KRAS H2AC18 ESR1 ERBB2
44	neuroblastoma	30.6	TP53 PIK3CA H19 ESR1 ERBB2 BAX
45	diffuse gastric cancer	30.6	TP53 PIK3CA KRAS ERBB2
46	lung squamous cell carcinoma	30.6	TP53 PIK3CA KRAS H2AC18 AKT1
47	papillary adenocarcinoma	30.6	TP53 PIP KRAS ERBB2
48	squamous cell carcinoma, head and neck	30.6	TP53 PIK3CA H2AC18 H19 ERBB2 AKT1
49	breast ductal carcinoma	30.6	TP53 PIP PGR ESR1 ERBB2
50	testicular disease	30.6	TP53 H2AC18 ESR1 AKT1

Graphical network of the top 20 diseases related to Breast Adenocarcinoma:

Sources

Symptoms & Phenotypes for Breast Adenocarcinoma

GenomeRNAi Phenotypes related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

²⁵ (show all 14)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	10.62	KRAS KSR1 PIK3CA
2	Decreased viability	GR00055-A-2	10.62	KRAS KSR1 PIK3CA
3	Decreased viability	GR00055-A-3	10.62	KRAS KSR1
4	Decreased viability	GR00106-A-0	10.62	KRAS KSR1
5	Decreased viability	GR00221-A-1	10.62	AKT1 ESR1 KRAS KSR1 PIK3CA
6	Decreased viability	GR00221-A-2	10.62	AKT1 ESR1 KRAS KSR1 PIK3CA
7	Decreased viability	GR00221-A-3	10.62	AKT1 KSR1 ERBB2
8	Decreased viability	GR00221-A-4	10.62	AKT1 ESR1 KSR1 PIK3CA ERBB2
9	Decreased viability	GR00249-S	10.62	AKT1 KSR1
10	Decreased viability	GR00301-A	10.62	KRAS
11	Decreased viability	GR00381-A-1	10.62	KRAS
12	Decreased viability	GR00386-A-1	10.62	ESR1
13	Decreased viability	GR00402-S-2	10.62	ESR1 PIK3CA
14	Decreased viability in pancreas lineage	GR00235-A	8.62	PGR TP53

MGI Mouse Phenotypes related to Breast Adenocarcinoma:

⁴⁵ (show all 15)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.32	AKT1 ANXA8 BAX CALCA ERBB2 ESR1
2	neoplasm	MP:0002006	10.29	AKT1 BAX CALCA ERBB2 ESR1 KRAS
3	muscle	MP:0005369	10.25	AKT1 BAX ERBB2 ESR1 KRAS PGR
4	cellular	MP:0005384	10.22	AKT1 ANXA8 BAX ERBB2 ESR1 KRAS
5	normal	MP:0002873	10.19	AKT1 CALCA ERBB2 ESR1 KRAS PGR
6	endocrine/exocrine gland	MP:0005379	10.16	AKT1 BAX ERBB2 ESR1 KRAS PGR
7	limbs/digits/tail	MP:0005371	10.15	BAX C1RL ERBB2 ESR1 KRAS PGR
8	immune system	MP:0005387	10.13	AKT1 ANXA8 BAX ESR1 KRAS KSR1
9	cardiovascular system	MP:0005385	10.11	AKT1 CALCA ERBB2 ESR1 KRAS PGR
10	embryo	MP:0005380	10.09	AKT1 CALCA ERBB2 ESR1 KRAS PGR
11	no phenotypic analysis	MP:0003012	10.07	ESR1 KRAS PGR PIK3CA RB1CC1 TNFSF11
12	skeleton	MP:0005390	9.97	AKT1 BAX C1RL CALCA ERBB2 ESR1
13	respiratory system	MP:0005388	9.91	AKT1 BAX CALCA ERBB2 ESR1 KRAS
14	hematopoietic system	MP:0005397	9.77	AKT1 ANXA8 BAX ERBB2 ESR1 KRAS
15	integument	MP:0010771	9.4	AKT1 CALCA ERBB2 ESR1 KRAS KSR1

Sources

Drugs & Therapeutics for Breast Adenocarcinoma

Drugs for Breast Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 130)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Zoledronic acid

Approved

Phase 3

118072-93-8

68740

Cyclophosphamide

Approved, Investigational

Phase 3

50-18-0, 6055-19-2

2907

Doxorubicin

Approved, Investigational

Phase 3

23214-92-8

31703

Carboplatin

Approved

Phase 3

41575-94-4

10339178 38904

Atezolizumab

Approved, Investigational

Phase 3

1380723-44-3

Pertuzumab

Approved

Phase 3

380610-27-5

Trastuzumab

Approved, Investigational

Phase 3

180288-69-1

Docetaxel

Approved, Investigational

Phase 3

114977-28-5

148124

Letrozole

Approved, Investigational

Phase 3

112809-51-5

3902

Sodium citrate

Approved, Investigational

Phase 3

68-04-2

23431961

Tamoxifen

Approved

Phase 3

10540-29-1, 54965-24-1

2733526

Bevacizumab

Approved, Investigational

Phase 3

216974-75-3

135329020

Exemestane

Approved, Investigational

Phase 3

107868-30-4

60198

Goserelin

Approved

Phase 3

65807-02-5

5311128 47725

Anastrozole

Approved, Investigational

Phase 3

120511-73-1

2187

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 3

77-92-9

311

Entinostat

Investigational

Phase 3

209783-80-2

4261

Immunosuppressive Agents

Phase 3

Antirheumatic Agents

Phase 3

Anti-Bacterial Agents

Phase 3

Alkylating Agents

Phase 3

Antineoplastic Agents, Alkylating

Phase 3

Antibiotics, Antitubercular

Phase 3

Liposomal doxorubicin

Phase 3

Immunoglobulins, Intravenous

Phase 3

Immunoglobulins

Phase 3

Immunoglobulin G

Phase 3

Hormones

Phase 3

Angiogenesis Inhibitors

Phase 3

Antibodies

Phase 3

Antibodies, Monoclonal

Phase 3

Trastuzumab biosimilar HLX02

Phase 3

Antineoplastic Agents, Immunological

Phase 3

Taxane

Phase 3

108169

Antineoplastic Agents, Hormonal

Phase 3

Estrogens

Phase 3

Estrogen Receptor Modulators

Phase 3

Estrogen Receptor Antagonists

Phase 3

Estrogen Antagonists

Phase 3

Hormone Antagonists

Phase 3

Aromatase Inhibitors

Phase 3

Citrate

Phase 3

Selective Estrogen Receptor Modulators

Phase 3

Endothelial Growth Factors

Phase 3

Mitogens

Phase 3

Histone Deacetylase Inhibitors

Phase 3

Halichondrin B

Phase 3

5915307

Talazoparib

Approved, Investigational

Phase 2

1207456-01-6

135565082

Ethanol

Approved

Phase 2

64-17-5

702

Coconut

Approved

Phase 2

Interventional clinical trials:

(show all 50)

#	Name	Status	NCT ID	Phase	Drugs
1	Association of HSD3B1 Genotype With Response to Preoperative Letrozole Therapy Among Postmenopausal Women With Estrogen-Receptor Positive (ER+) HER2/Neu-Negative (HER2-) Invasive Carcinomas of the Breast	Recruiting	NCT05183828	Phase 4	Letrozole
2	Randomized Double-blind Study to Compare Two Neo-adjuvant Treatments: an Anti-aromatase vs SERM for Postmenopausal Women With ER+ Breast Adenocarcinoma: Effect on Intermediate Predictive Biological Response to Treatment.	Completed	NCT00949598	Phase 3	letrozole;tamoxifen citrate
3	A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer	Completed	NCT00869206	Phase 3	zoledronic acid
4	Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer	Completed	NCT00005970	Phase 3	Aromatase Inhibition Therapy;Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel;Tamoxifen Citrate
5	Randomised Multicentric Phase III Study Evaluating the Efficacy of Cicaderma vs Standard Management of Each Site in Preventing Radiodermatitis After Adjuvant Post-operative Breast Irradiation in Patients With Non-metastatic Breast Cancer	Recruiting	NCT04300829	Phase 3	cicaderma + simple hygiene rules
6	A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer	Recruiting	NCT02488967	Phase 3	Carboplatin;Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel
7	A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer	Active, not recruiting	NCT03199885	Phase 3	Atezolizumab;Docetaxel;Paclitaxel
8	A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer	Active, not recruiting	NCT00433511	Phase 3	Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel
9	A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer	Active, not recruiting	NCT02115282	Phase 3	Entinostat;Exemestane;Goserelin Acetate
10	Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial	Active, not recruiting	NCT00310180	Phase 3	Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate
11	A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer	Suspended	NCT02037529	Phase 3	Eribulin Mesylate;Paclitaxel
12	A Pilot Study of Talazoparib as a Neoadjuvant Study in Patients With a Diagnosis of Invasive Breast Cancer and a Deleterious BRCA Mutation	Completed	NCT02282345	Phase 2	Talazoparib
13	Bacterial Cellulose-monolaurin Hydrogel for Preventing Therapy-induced High-grade Acute Dermatitis Among Filipinos With Breast Adenocarcinoma: a Pilot Randomized Controlled Trial	Recruiting	NCT05079763	Phase 2
14	Phase II Trial to Evaluate Immune-Related Biomarkers for Pathological Response in Stage II-III HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Subsequent Randomization to Multi-Epitope HER2 Vaccine vs. Placebo in Patients With Residual Disease Post-Neoadjuvant Chemotherapy	Recruiting	NCT04197687	Phase 2
15	Assessing the Cosmesis and Toxicity of Partial Breast Irradiation Using Proton Beam Irradiation	Recruiting	NCT01245712	Phase 2
16	Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors	Recruiting	NCT05001282	Phase 1, Phase 2	ELU001
17	Comprehensive Single-Cell Transcriptional Analysis of Aromatase Inhibitor-Resistant Breast Cancer	Recruiting	NCT05447910	Phase 2	Letrozole
18	Phase I/II Trial of Pembrolizumab in Combination With Binimetinib in Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer	Active, not recruiting	NCT03106415	Phase 1, Phase 2	Binimetinib
19	Phase I/II Trial of BINTRAFUSP ALFA (M7824) and Pimasertib for Treatment of Intracranial Metastases	Active, not recruiting	NCT04789668	Phase 1, Phase 2	Bintrafusp Alfa;Pimasertib
20	An Open Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With HER2+ Breast Cancer Treated With Neratinib With or Without Trastuzumab	Active, not recruiting	NCT03094052	Phase 2	Neratinib;Loperamide;Diphenoxylate Hydrochloride/Atropine Sulfate
21	A Stratified, Multicenter Phase II Trial of Transdermal CR1447 (4-OH-testosterone) in Endocrine Responsive-HER2 Negative and Triple Negative-androgen Receptor Positive Metastatic or Locally Advanced Breast Cancer	Active, not recruiting	NCT02067741	Phase 2	CR1447
22	T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy	Active, not recruiting	NCT02957968	Phase 2	Doxorubicin;Cyclophosphamide;Paclitaxel;Carboplatin;Decitabine;Pembrolizumab
23	A Phase 1-2 Multicenter, Open Label Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer	Active, not recruiting	NCT03250676	Phase 1, Phase 2	H3B-6545
24	Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a PDL-1 Inhibitor in Patients With Triple Negative Breast Cancer	Active, not recruiting	NCT02530489	Phase 2	Atezolizumab;Nab-paclitaxel
25	Phase II Prospective Open Label Study of Pertuzumab, Trastuzumab, and Nab-Paclitaxel in Patients With HER-2 Positive Advanced Breast Cancer	Active, not recruiting	NCT01730833	Phase 2	paclitaxel albumin-stabilized nanoparticle formulation
26	A Phase I-II Study of PTX-200 Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Metastatic and Locally Advanced Breast Cancer	Terminated	NCT01697293	Phase 1, Phase 2	Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel;Triciribine Phosphate
27	Phase II Trial of CO2RE Laser for Patients With Stage 0-III Hormone Receptor-Positive Breast Cancer on Aromatase Inhibitors With Vulvovaginal Atrophy	Withdrawn	NCT03666819	Phase 2
28	Combined Modality Radioimmunotherapy For Metastatic Breast Adenocarcinoma With Two Cycles Of Escalating Dose 90Y-DOTA-peptide-m170 and Fixed, Low Dose Paclitaxel With Blood Stem Cell Support And Cyclosporin For HAMA Suppression	Unknown status	NCT00009763	Phase 1	cyclosporine;paclitaxel
29	A Phase 1 Study of Abemaciclib and Niraparib as Neoadjuvant Therapy in Hormone Receptor Positive (HR+) HER2 Negative (HER2-) Breast Cancer	Recruiting	NCT04481113	Phase 1	Abemaciclib;Niraparib Tosylate Monohydrate
30	A Pilot Trial of Preoperative Oral Microbiota-Based Investigational New Drug, RBX7455 to Target Immune Response in Patients With Operable Stage I-III Breast Cancer	Recruiting	NCT04139993	Phase 1	Microbiota-based Formulation RBX7455
31	An Open Label, Multicenter, Dose-Finding Clinical Phase 1 Study of ASN004 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy in Patients With Advanced Malignant Solid Tumors	Recruiting	NCT04410224	Phase 1	ASN004
32	Phase I Trial of Intratumoral Administration of a Measles Virus Derivative Expressing the Helicobacter Pylori Neutrophil-Activating Protein (NAP) (MV-s-NAP) in Patients With Metastatic Breast Cancer	Recruiting	NCT04521764	Phase 1
33	Pilot Safety and Feasibility Study of an In Vivo Sensitivity Screen Using a Direct Tumor Microinjection Technique and FDG-PET	Recruiting	NCT03432741	Phase 1	Belinostat;Carfilzomib;Copanlisib Hydrochloride;Fludeoxyglucose F-18;Gemcitabine Hydrochloride;Romidepsin
34	A Phase I, Single Arm, Prospective Study to Evaluate the Treatment of Genitourinary Syndrome of Menopause With Platelet Rich Plasma (PRP) in Women With a History of Breast Cancer	Recruiting	NCT04535323	Phase 1
35	A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of PT199 Administered Alone and in Combination With a PD-1 Inhibitor in Adult Patients With Advanced Solid Tumors	Recruiting	NCT05431270	Phase 1	PT199;Anti-PD-1 monoclonal antibody
36	A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors	Active, not recruiting	NCT02453620	Phase 1	Entinostat
37	Phase Ib Study of Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Patients With Metastatic Breast Cancer	Terminated	NCT02824575	Phase 1	Rebastinib;Paclitaxel;Eribulin Mesylate
38	REINA: A Phase I Study of Radiation Enhanced IL 12-Necrosis Attraction in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients	Withdrawn	NCT04756505	Phase 1	Bintrafusp Alfa
39	Prognostic Value of Quantitative p63 Immunostaining in Adenocarcinoma of Lung, Breast, and Pancreas	Unknown status	NCT01942629
40	Search for Genetic Factors Predictive of Response to Chemotherapy in Patients With or Who Has a Mammary Adenocarcinoma in Neo-adjuvant or Metastatic Setting	Unknown status	NCT00959556
41	Adjuvant Dose-dense Sequential Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-risk Breast Cancer: A Hellenic Cooperative Oncology Group (HeCOG) Study	Completed	NCT04829890
42	Evaluation of Myocardial Changes During BReast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI - The EMBRACE MRI Study	Recruiting	NCT02306538
43	A Pilot Safety Study for Performing MRI in Patients Who Have Breast Tissue Expanders	Recruiting	NCT04769960
44	Hypofractionated Regional Nodal Irradiation Phase 2 Clinical Trial for Women With Breast Cancer - HeNRIetta	Recruiting	NCT02515110
45	Engineering Gut Microbiome to Target Cancer-Immune Microenvironment in Breast and Lung Cancer	Recruiting	NCT04857697	Early Phase 1	Probiotic
46	Immune Response to Anti-HER2 Therapies	Recruiting	NCT04517838
47	A Pilot Study of the Associations Between Chemotherapy-Induced Nausea in Breast Cancer Patients and Gut Microbiome Composition Profiles	Recruiting	NCT05417867
48	A Phase II Study of Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer: Introduction of a Novel Form of Accelerated Partial Breast Radiotherapy	Terminated	NCT03137693
49	Impact of Breast Cancer Treatment on Joint Health, Cartilage Composition, and Bone Structure in the Knee and Hand	Terminated	NCT04876378
50	Comparative Effects of Ribociclib and Palbociclib on Circulating and Tumor Infiltrating Myeloid Cells in Metastatic Breast Cancer Patients	Withdrawn	NCT05244434

Search NIH Clinical Center for Breast Adenocarcinoma

Sources

Genetic Tests for Breast Adenocarcinoma

Genetic tests related to Breast Adenocarcinoma:

#	Genetic test	Affiliating Genes
1	Breast Adenocarcinoma ²⁸

Sources

Anatomical Context for Breast Adenocarcinoma

Organs/tissues related to Breast Adenocarcinoma:

MalaCards : Breast, Lymph Node, Lung, Endothelial, Bone Marrow, Bone, Myeloid

Sources

Publications for Breast Adenocarcinoma

Articles related to Breast Adenocarcinoma:

(show top 50) (show all 5075)

#	Title	Authors	PMID	Year
1	Somatic PIK3CA Mutations in Sporadic Cerebral Cavernous Malformations. ⁵	Peyre M...Kalamarides M	34496175	2021
2	Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. ⁵	Van Keymeulen A...Blanpain C	26266985	2015
3	PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. ⁵	Koren S...Bentires-Alj M	26266975	2015
4	Oculoectodermal syndrome is a mosaic RASopathy associated with KRAS alterations. ⁵	Peacock JD...Steensma M	25808193	2015
5	Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. ⁵	Rios JJ...Ezaki M	23100325	2013
6	De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. ⁵	Riviere JB...Dobyns WB	22729224	2012
7	De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. ⁵	Lee JH...Gleeson JG	22729223	2012
8	Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. ⁵	Lindhurst MJ...Semple RK	22729222	2012
9	Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. ⁵	Kurek KC...Warman ML	22658544	2012
10	A mosaic activating mutation in AKT1 associated with the Proteus syndrome. ⁵	Lindhurst MJ...Biesecker LG	21793738	2011
11	Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation. ⁵	Takagi M...Mizutani S	21063026	2011
12	Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. ⁵	Hafner C...Real FX	17673550	2007
13	A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. ⁵	Carpten JD...Thomas JE	17611497	2007
14	Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. ⁵	Matsuda K...Koike K	17332249	2007
15	PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. ⁵	Lee JW...Lee SH	15608678	2005
16	Mutation of the PIK3CA gene in ovarian and breast cancer. ⁵	Campbell IG...Phillips WA	15520168	2004
17	High frequency of mutations of the PIK3CA gene in human cancers. ⁵	Samuels Y...Velculescu VE	15016963	2004
18	Truncating mutations of RB1CC1 in human breast cancer. ⁵	Chano T...Ikegawa S	12068296	2002
19	Transcriptional map of 170-kb region at chromosome 11p15.5: identification and mutational analysis of the BWR1A gene reveals the presence of mutations in tumor samples. ⁵	Schwienbacher C...Negrini M	9520460	1998
20	A new mutation of exon 5 of the P53 gene in breast cancer. ⁵	Carrere N...Cheyrou A	8364550	1993
21	Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer. ⁵	Chen LC...Liu E	1673792	1991
22	The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB231. ⁵	Kozma SC...Hynes NE	3627975	1987
23	Enhancing the photoinduced via a novel nano-combination of terbium oxide and nickel oxide on graphene oxide surface: Cytotoxicity and water treatment. ⁶²	Khalaf EI...El-Mehasseb IM	36228488	2023
24	Feasibility and early toxicity of intraoperative radiotherapy for breast cancer using the papillon + system: First results. ⁶²	Chand-Fouche ME...Barranger E	36353651	2023
25	Coriolus versicolor and its bioactive molecule are potential immunomodulators against cancer cell metastasis via inactivation of MAPK pathway. ⁶²	Yang CL...Chan GC	36208821	2023
26	Novel Ru(II)-bipyridine/phenanthroline-lapachol complexes as potential anti-cancer agents. ⁶²	De Grandis RA...Resende FA	36155170	2022
27	Host-guest complexation of cyclophosphamide by carboxylatopillar[6]arene for increasing stability and enhancing its curative effect on breast carcinoma. ⁶²	Gao J...Li C	36371019	2022
28	Synthesis of steroidal dihydropyrazole derivatives using green ZnO NPs and evaluation of their anticancer and antioxidant activity. ⁶²	Ansari A...Shamsuzzaman	36152868	2022
29	Synthesis, characterization, antioxidant potential, and cytotoxicity screening of new Cu(II) complexes with 4-(arylchalcogenyl)-1H-pyrazoles ligands. ⁶²	Pinheiro AC...Saffi J	36183642	2022
30	Thiopyrano[2,3-d]thiazole structures as promising scaffold with anticancer potential. ⁶²	Finiuk N...Lesyk R	36328132	2022
31	Novel spirooxindole based benzimidazole scaffold: In vitro, nanoformulation and in vivo studies on anticancer and antimetastatic activity of breast adenocarcinoma. ⁶²	Barakat A...El-Senduny FF	36174446	2022
32	S-phase arrest and apoptosis in human breast adenocarcinoma MCF-7 cells via mitochondrial dependent pathway induced by tricyclohexylphosphine gold (I) n-mercaptobenzoate complexes. ⁶²	Pian AK...Hamid RA	36375571	2022
33	DNA binding and cleavage, BRCA1 gene interaction, antiglycation and anticancer studies of transition metal complexes of sulfonamides. ⁶²	Akhtar A...Asiri AM	35182295	2022
34	Antioxidant and cytotoxic activities of selected salicylidene imines: experimental and computational study. ⁶²	Brankovic J...Petrovic VP	35147861	2022
35	Identification of natural products and FDA-approved drugs for targeting cancer stem cell (CSC) propagation. ⁶²	Bonuccelli G...Lisanti MP	36455875	2022
36	Development of benzene and benzothiazole-sulfonamide analogues as selective inhibitors of the tumor-associated carbonic anhydrase IX. ⁶²	Manzoor S...Hoda N	36201858	2022
37	Synthesis, characterization, and biological properties of mono-, di- and poly-nuclear bismuth(III) halide complexes containing thiophene-2-carbaldehyde thiosemicarbazones. ⁶²	Turk K...Ozturk II	36113327	2022
38	Novel zinc(II)-curcumin molecular probes bearing berberine and jatrorrhizine derivatives as potential mitochondria-targeting anti-neoplastic drugs. ⁶²	Zhang SH...Tan H	36115208	2022
39	New Jatrophane-Type Diterpenoids from Euphorbia kansui as Potential MDR Reversal Agents. ⁶²	Zheng Q...Ma LF	36156394	2022
40	D-Mannose-appended 5,15-diazaporphyrin for photodynamic therapy. ⁶²	Ali LMA...Shinokubo H	36043857	2022
41	Olive Leaf Extracts for a Green Synthesis of Silver-Functionalized Multi-Walled Carbon Nanotubes. ⁶²	Alhajri HM...Alsaab HO	36412865	2022
42	Carbon Nanoparticles Extracted from Date Palm Fronds for Fluorescence Bioimaging: In Vitro Study. ⁶²	Mohiuddin SMUG...Salah N	36412859	2022
43	Thermosensitive Liposomes Encapsulating Nedaplatin and Picoplatin Demonstrate Enhanced Cytotoxicity against Breast Cancer Cells. ⁶²	Fahmy SA...Shoeib T	36440163	2022
44	Phenotypic Changes in Mammary Adenocarcinoma (4T1) cells In Vitro after Treatment with Carcinosinum. ⁶²	Silva TCD...Bonamin LV	35477183	2022
45	The effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in vivo. ⁶²	Goleh Z...Toliyat T	36434467	2022
46	Trailing TRAIL resistance in human breast adenocarcinoma cells with Trichostatin A and Zebularine. ⁶²	Wong SHM...Ngai SC	36380402	2022
47	Epigenetic Mechanisms in Breast Adenocarcinoma: Novel DNA Methylation Patterns. ⁶²	Metaxas GI...Dimitrakakis C	36340455	2022
48	Comparative Study of Cytotoxic and Membranotropic Properties of Betulinic Acid-F16 Conjugate on Breast Adenocarcinoma Cells (MCF-7) and Primary Human Fibroblasts. ⁶²	Belosludtsev KN...Dubinin MV	36428470	2022
49	Anticancer potential of Marina Crystal Minerals (MCM) against the growth of murine mammary adenocarcinoma cells in vivo. ⁶²	Ghoneum M...Badr El-Din NK	36371853	2022
50	Docking and molecular dynamics predicted B-DNA and dihydropyrimidinone selenoesters interactions elucidating antiproliferative effects on breast adenocarcinoma cells. ⁶²	Benassi JC...Pedrosa RC	33847252	2022

Sources

Genes for Breast Adenocarcinoma

Genes related to Breast Adenocarcinoma (6 elite genes):

(show top 50) (show all 124)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	TP53	Tumor Protein P53	Protein Coding	407.2	Pathogenic ⁵ DISEASES inferred ¹⁴	1673792 8364550
2	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	406.66	Pathogenic ⁵ DISEASES inferred ¹⁴	17611497 21793738
3	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	405.35	Pathogenic ⁵ DISEASES inferred ¹⁴	15016963 15520168 15608678 (more) 17673550 22658544 22729222 22729223 22729224 23100325 26266975 26266985 34496175
4	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	405.34	Pathogenic ⁵ DISEASES inferred ¹⁴	3627975 17332249 21063026 (more) 25808193
5	RB1CC1	RB1 Inducible Coiled-Coil 1	Protein Coding	403.89	Pathogenic ⁵ DISEASES inferred ¹⁴	12068296
6	SLC22A18	Solute Carrier Family 22 Member 18	Protein Coding	400	Pathogenic ⁵	9520460
7	H19	H19 Imprinted Maternally Expressed Transcript	RNA Gene	150	Experimental evidence: Regulation ³⁷	9811352
8	BAX	BCL2 Associated X, Apoptosis Regulator	Protein Coding	19.22	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Expressions (show sections)
9	CHMP2A	Charged Multivesicular Body Protein 2A	Protein Coding	11.28	DISEASES inferred ¹⁴ GeneCards inferred via : Gene name (show sections)
10	KSR1	Kinase Suppressor Of Ras 1	Protein Coding	10.95	DISEASES inferred ¹⁴ GeneCards inferred via : Summaries (show sections)
11	H2AC18	H2A Clustered Histone 18	Protein Coding	8.33	DISEASES inferred ¹⁴ ¹⁴
12	ANXA8	Annexin A8	Protein Coding	8.21	DISEASES inferred ¹⁴ ¹⁴
13	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	7.83	DISEASES inferred ¹⁴
14	CALCA	Calcitonin Related Polypeptide Alpha	Protein Coding	7.55	DISEASES inferred ¹⁴
15	ESR1	Estrogen Receptor 1	Protein Coding	7.52	DISEASES inferred ¹⁴
16	TNFSF11	TNF Superfamily Member 11	Protein Coding	7.33	DISEASES inferred ¹⁴
17	VCP	Valosin Containing Protein	Protein Coding	7.14	DISEASES inferred ¹⁴
18	PGR	Progesterone Receptor	Protein Coding	7.06	DISEASES inferred ¹⁴
19	C1RL	Complement C1r Subcomponent Like	Protein Coding	6.98	GeneCards inferred via : Expressions (show sections)
20	PIP	Prolactin Induced Protein	Protein Coding	6.98	DISEASES inferred ¹⁴
21	LIN28B	Lin-28 Homolog B	Protein Coding	6.93	GeneCards inferred via : Functions (show sections)
22	SERPINA3	Serpin Family A Member 3	Protein Coding	6.84	DISEASES inferred ¹⁴ ¹⁴
23	KRT7	Keratin 7	Protein Coding	6.77	DISEASES inferred ¹⁴
24	CASP3	Caspase 3	Protein Coding	6.72	DISEASES inferred ¹⁴
25	SQSTM1	Sequestosome 1	Protein Coding	6.68	DISEASES inferred ¹⁴
26	BCL2	BCL2 Apoptosis Regulator	Protein Coding	6.63	DISEASES inferred ¹⁴
27	EGF	Epidermal Growth Factor	Protein Coding	6.63	DISEASES inferred ¹⁴
28	FDPS	Farnesyl Diphosphate Synthase	Protein Coding	6.62	DISEASES inferred ¹⁴
29	PTH	Parathyroid Hormone	Protein Coding	6.59	DISEASES inferred ¹⁴
30	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	6.58	DISEASES inferred ¹⁴
31	ANXA5	Annexin A5	Protein Coding	6.58	DISEASES inferred ¹⁴
32	EGFR	Epidermal Growth Factor Receptor	Protein Coding	6.56	DISEASES inferred ¹⁴
33	BGLAP	Bone Gamma-Carboxyglutamate Protein	Protein Coding	6.54	DISEASES inferred ¹⁴
34	LCOR	Ligand Dependent Nuclear Receptor Corepressor	Protein Coding	6.52	DISEASES inferred ¹⁴ ¹⁴
35	ACP5	Acid Phosphatase 5, Tartrate Resistant	Protein Coding	6.51	DISEASES inferred ¹⁴
36	ACTB	Actin Beta	Protein Coding	6.49	DISEASES inferred ¹⁴
37	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	6.35	DISEASES inferred ¹⁴
38	ALB	Albumin	Protein Coding	6.35	DISEASES inferred ¹⁴
39	CDH1	Cadherin 1	Protein Coding	6.34	DISEASES inferred ¹⁴
40	CCND1	Cyclin D1	Protein Coding	6.29	DISEASES inferred ¹⁴
41	GAPDH	Glyceraldehyde-3-Phosphate Dehydrogenase	Protein Coding	6.23	DISEASES inferred ¹⁴
42	TNFRSF11B	TNF Receptor Superfamily Member 11b	Protein Coding	6.22	DISEASES inferred ¹⁴
43	CASP9	Caspase 9	Protein Coding	6.17	DISEASES inferred ¹⁴
44	IL6	Interleukin 6	Protein Coding	6.17	DISEASES inferred ¹⁴
45	TNF	Tumor Necrosis Factor	Protein Coding	6.16	DISEASES inferred ¹⁴
46	TNFRSF11A	TNF Receptor Superfamily Member 11a	Protein Coding	6.16	DISEASES inferred ¹⁴
47	CD8A	CD8a Molecule	Protein Coding	6.16	DISEASES inferred ¹⁴
48	CYCS	Cytochrome C, Somatic	Protein Coding	6.15	DISEASES inferred ¹⁴
49	MMP9	Matrix Metallopeptidase 9	Protein Coding	6.13	DISEASES inferred ¹⁴
50	SRC	SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase	Protein Coding	6.11	DISEASES inferred ¹⁴

Sources

Variations for Breast Adenocarcinoma

ClinVar genetic disease variations for Breast Adenocarcinoma:

⁵ (show all 11)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	RB1CC1	NC_000008.11:g.52623770_52685461del	DEL	Pathogenic	3976		GRCh37: 8:53536328-53598019 GRCh38: 8:52623768-52685459
2	RB1CC1	nsv1067861	DEL	Pathogenic	3977		GRCh37: 8:53537321-53574220 GRCh38: 8:52624761-52661660
3	SLC22A18	NM_002555.6(SLC22A18):c.864_865ins[NC_000011.10:g.2919738_2919848]	INSERT	Pathogenic	6976		GRCh37: GRCh38:
4	PIK3CA	NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu)	SNV	Pathogenic	13653	rs121913279	GRCh37: 3:178952085-178952085 GRCh38: 3:179234297-179234297
5	PIK3CA	NM_006218.4(PIK3CA):c.1636C>G (p.Gln546Glu)	SNV	Pathogenic	13654	rs121913286	GRCh37: 3:178936094-178936094 GRCh38: 3:179218306-179218306
6	PIK3CA	NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)	SNV	Pathogenic	13655	rs104886003	GRCh37: 3:178936091-178936091 GRCh38: 3:179218303-179218303
7	TP53	NM_000546.6(TP53):c.451C>A (p.Pro151Thr)	SNV	Pathogenic	12369	rs28934874	GRCh37: 17:7578479-7578479 GRCh38: 17:7675161-7675161
8	TP53	NM_000546.6(TP53):c.451C>T (p.Pro151Ser)	SNV	Pathogenic	12370	rs28934874	GRCh37: 17:7578479-7578479 GRCh38: 17:7675161-7675161
9	KRAS	NM_004985.5(KRAS):c.38G>A (p.Gly13Asp)	SNV	Pathogenic	12580	rs112445441	GRCh37: 12:25398281-25398281 GRCh38: 12:25245347-25245347
10	PIK3CA	NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)	SNV	Pathogenic	13652	rs121913279	GRCh37: 3:178952085-178952085 GRCh38: 3:179234297-179234297
11	AKT1	NM_001382430.1(AKT1):c.49G>A (p.Glu17Lys)	SNV	Pathogenic	13983	rs121434592	GRCh37: 14:105246551-105246551 GRCh38: 14:104780214-104780214

Sources

Expression for Breast Adenocarcinoma

Search GEO for disease gene expression data for Breast Adenocarcinoma.

Sources

Pathways for Breast Adenocarcinoma

Pathways related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 62)

#	Super pathways	Score	Top Affiliating Genes
1	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.76	VCP TP53 SLC22A18 PIK3CA KSR1 KRAS
2	Signal Transduction ⁶⁶	13.62	VCP TP53 PIK3CA PGR KSR1 KRAS
3	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.42	TP53 TNFSF11 PIP KRAS ERBB2 BAX
4	RAF/MAP kinase cascade ⁶⁶ Show member pathways Diseases of signal transduction by growth factor receptors and second messengers ⁶⁶ MAPK family signaling cascades ⁶⁶ MAPK1/MAPK3 signaling ⁶⁶	13.38	VCP PIK3CA KSR1 KRAS ESR1 ERBB2
5	ESR-mediated signaling ⁶⁶ Show member pathways Estrogen-dependent gene expression ⁶⁶ RUNX1 regulates estrogen receptor mediated transcription ⁶⁶ Signaling by Nuclear Receptors ⁶⁶	12.99	PIK3CA PGR KRAS H2AC18 ESR1 AKT1
6	TNFR1 Pathway ⁶⁴ Show member pathways Apoptosis ⁷⁴ Apoptosis and survival TNFR1 signaling pathway ²² Apoptosis modulation by HSP70 ⁷⁴ Apoptosis through Death Receptors ⁶⁴ Apoptotic Pathways Triggered By HIV1 ⁶⁴ Ceramide signaling pathway ⁶¹ DR3 Signaling ⁶⁴ GITR Pathway ⁶⁴ HIV-1 Nef: Negative effector of Fas and TNF-alpha ⁶¹ Stimulation of the cell death response by PAK-2p34 ⁶⁶ TNF Signaling ⁶⁴ TNF-related weak inducer of apoptosis (TWEAK) signaling pathway ⁷⁴ TRAIL Pathway ⁶⁴ TWEAK Pathway ⁶⁴	12.93	TP53 TNFSF11 PIK3CA KSR1 BAX AKT1
7	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.85	TP53 PIK3CA KRAS BAX AKT1
8	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.77	AKT1 BAX ERBB2 ESR1 KRAS PGR
9	Malignant pleural mesothelioma ⁷⁴	12.71	AKT1 BAX PIK3CA RB1CC1 TP53
10	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.68	AKT1 BAX ERBB2 KRAS PIK3CA TP53
11	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.54	TP53 PIK3CA KRAS ERBB2 BAX AKT1
12	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.48	TP53 PIK3CA KRAS ERBB2 AKT1
13	Development Dopamine D2 receptor transactivation of EGFR ²² Show member pathways Chemotaxis CXCR4 signaling pathway ²² Development Alpha-2 adrenergic receptor activation of ERK ²² Extra-nuclear estrogen signaling ⁶⁶	12.42	PIK3CA KRAS ESR1 AKT1
14	Development VEGF signaling via VEGFR2 - generic cascades ²² Show member pathways Development VEGF signaling and activation ²² VEGF - VEGF R2 Signaling Pathways ⁶⁵	12.41	PIK3CA KRAS ESR1 AKT1
15	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.39	TP53 PIK3CA ESR1 ERBB2 BAX AKT1
16	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.35	TP53 PIK3CA KRAS ERBB2 BAX AKT1
17	Development Ligand-independent activation of ESR1 and ESR2 ²² Show member pathways Transcription CREB pathway ²² Transcription PPAR Pathway ²²	12.33	PIK3CA ESR1 ERBB2 AKT1
18	Development IGF-1 receptor signaling ²² Show member pathways Immune response IL-4 signaling pathway ²² Signal transduction AKT signaling ²²	12.27	TP53 PIK3CA BAX AKT1
19	Ras signaling ⁷⁴	12.26	PIK3CA KSR1 KRAS AKT1
20	Colorectal Cancer Metastasis ⁶⁴	12.21	TP53 KRAS BAX AKT1
21	Epithelial to mesenchymal transition in colorectal cancer ⁷⁴	12.19	TP53 PIK3CA KRAS AKT1
22	NGF Pathway ⁶⁴ Show member pathways MAPK and NFkB signaling pathways inhibited by Yersinia YopJ ⁷⁴ TRKA Signaling ⁶⁴	12.18	TP53 KRAS BAX AKT1
23	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.16	TP53 PIK3CA BAX AKT1
24	mTOR Signaling ⁶⁵	12.1	TP53 KRAS ERBB2 AKT1
25	Integrated breast cancer pathway ⁷⁴	12.1	TP53 KRAS ESR1 BAX AKT1
26	Signaling by ERBB2 ⁶⁶ Show member pathways Downregulation of ERBB2 signaling ⁶⁶ Downregulation of ERBB2:ERBB3 signaling ⁶⁶ ERBB2 Activates PTK6 Signaling ⁶⁶ ERBB2 Regulates Cell Motility ⁶⁶ GRB7 events in ERBB2 signaling ⁶⁶	12.04	PIK3CA KRAS ERBB2 AKT1
27	MAPK Pathway ⁷⁰ Show member pathways Toll-like Receptor Pathway ⁷⁰	12.02	TP53 PIK3CA ERBB2 AKT1
28	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ⁶¹ Nuclear signaling by ERBB4 ⁶⁶	12.02	PIK3CA PGR KRAS ESR1 ERBB2
29	Development EGFR signaling via small GTPases ²² Show member pathways Development EGFR signaling via PIP3 ²² Development PDGF signaling via MAPK cascades ²²	11.98	PIK3CA KRAS ERBB2 AKT1
30	TGF-beta Signaling Pathways ⁶⁵	11.89	KRAS ESR1 AKT1
31	Small cell lung cancer ⁷⁴	11.89	TP53 PIK3CA BAX AKT1
32	DNA damage response (only ATM dependent) ⁷⁴	11.81	BAX ERBB2 KRAS PIK3CA TP53
33	MAPK Signaling: Oxidative Stress ⁶⁵	11.79	TP53 KRAS BAX
34	Glucocorticoid receptor regulatory network ⁶¹	11.78	TP53 BAX AKT1
35	VEGF Pathway (Tocris) ⁷⁰ Show member pathways Sorafenib Pharmacodynamics ⁶⁰	11.77	PIK3CA KRAS BAX AKT1
36	mTOR Pathway ⁷⁰ Show member pathways TGF-beta Pathway ⁷⁰	11.77	TP53 PIK3CA KRAS AKT1
37	Burn wound healing ⁷⁴	11.76	AKT1 BAX TP53
38	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	11.71	TP53 TNFSF11 PIK3CA PGR KRAS ESR1
39	p75(NTR)-mediated signaling ⁶¹ Show member pathways Ceramide signalling ⁶⁶ NFG and proNGF binds to p75NTR ⁶⁶	11.7	TP53 PIK3CA AKT1
40	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	11.68	TP53 PIK3CA KSR1 KRAS ERBB2 BAX
41	Copper homeostasis ⁷⁴ Show member pathways Copper metabolism ⁷⁴ Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1) ⁶⁶	11.64	TP53 PIK3CA AKT1
42	Pathways affected in adenoid cystic carcinoma ⁷⁴	11.64	TP53 PIK3CA ERBB2 AKT1
43	Netrin-UNC5B signaling pathway ⁷⁴	11.58	TP53 PIK3CA AKT1
44	Clock-controlled autophagy in bone metabolism ⁷⁴	11.56	VCP TNFSF11 RB1CC1 CALCA AKT1
45	IL6-mediated signaling events ⁶¹	11.51	TNFSF11 PIK3CA AKT1
46	Bladder cancer ⁷⁴	11.45	ERBB2 KRAS TP53
47	Ovarian tumor domain proteases ⁶⁶	11.43	VCP TP53 ESR1
48	Kisspeptin/kisspeptin receptor system in the ovary ⁷⁴	11.42	PIK3CA KRAS AKT1
49	Head and neck squamous cell carcinoma ⁷⁴	11.42	TP53 PIK3CA KRAS ERBB2 AKT1
50	Integrated cancer pathway ⁷⁴	11.41	TP53 BAX AKT1

Sources

GO Terms for Breast Adenocarcinoma

Biological processes related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of gene expression	GO:0010629	9.97	TP53 PIK3CA PGR ESR1 AKT1
2	phosphatidylinositol 3-kinase signaling	GO:0014065	9.73	PIK3CA ERBB2 AKT1
3	positive regulation of gene expression	GO:0010628	9.44	TP53 TNFSF11 PIP PGR KRAS ERBB2
4	regulation of mitochondrial membrane permeability involved in apoptotic process	GO:1902108	9.33	TP53 BAX
5	positive regulation of RNA polymerase II transcription preinitiation complex assembly	GO:0045899	9.26	TP53 ESR1